Literature DB >> 24668006

Higher serum uric acid as a protective factor against incident osteoporotic fractures in Korean men: a longitudinal study using the National Claim Registry.

B-J Kim1, S Baek, S H Ahn, S H Kim, M-W Jo, S J Bae, H-K Kim, J Choe, G-M Park, Y-H Kim, S H Lee, G S Kim, J-M Koh.   

Abstract

UNLABELLED: In this large longitudinal study of 16,078 Korean men aged 50 years or older, we observed that baseline elevation of serum uric acid level significantly associated with a lower risk of incident fractures at osteoporosis-related sites during an average follow-up period of 3 years.
INTRODUCTION: Male osteoporosis and related fractures are becoming recognized as important public health concerns. Oxidative stress has detrimental effects on bone metabolism, and serum uric acid (UA) is known to be a strong endogenous antioxidant. In the present study, we performed a large longitudinal study with an average follow-up period of 3 years to clarify the role of UA on the risk of incident osteoporotic fractures (OFs).
METHODS: A total of 16,078 Korean men aged 50 years or older who had undergone comprehensive routine health examinations were enrolled. Incident fractures at osteoporosis-related sites (e.g., hip, spine, distal radius, and proximal humerus) that occurred after the baseline examinations were identified from the nationwide claims database of the Health Insurance Review and Assessment Service of Korea by using selected International Classification of Diseases, 10th revision codes.
RESULTS: In total, 158 (1.0 %) men developed incident OFs. The event rate was 33.1 per 10,000 person-years. Subjects without incident OFs had 6.0 % higher serum UA levels than subjects with OFs (P = 0.001). Multivariable-adjusted Cox proportional hazard analyses adjusted for age, body mass index, glomerular filtration rate, lifestyle factors, medical and drug histories, and the presence of baseline radiological vertebral fractures revealed that the hazard ratio per standard deviation increase of baseline UA levels for the development of incident OFs was 0.829 (95 % CI = 0.695-0.989, P = 0.038).
CONCLUSIONS: These data provide the epidemiological evidence that serum UA may act as a protective factor against the development of incident OFs in Korean men.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668006     DOI: 10.1007/s00198-014-2697-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  45 in total

1.  Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study.

Authors:  Dario Maggio; Mauro Barabani; Marco Pierandrei; M Cristina Polidori; Marco Catani; Patrizia Mecocci; Umberto Senin; Roberto Pacifici; Antonio Cherubini
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

2.  Burden of osteoporosis in adults in Korea: a national health insurance database study.

Authors:  Hyung Jin Choi; Chan Soo Shin; Yong-Chan Ha; Sunmee Jang; Sun-Mee Jang; Suhyun Jang; Su-Hyun Jang; Chanmi Park; Chan Mi Park; Hyun-Koo Yoon; Seong-Su Lee
Journal:  J Bone Miner Metab       Date:  2011-06-03       Impact factor: 2.626

3.  A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates.

Authors:  N J Miller; C Rice-Evans; M J Davies; V Gopinathan; A Milner
Journal:  Clin Sci (Lond)       Date:  1993-04       Impact factor: 6.124

4.  Uric acid levels predict survival in men with amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; May Zhang; Alejandro Quiroz Zárate; Matthew Jaffa; Hong Yu; Merit E Cudkowicz; Anne-Marie Wills
Journal:  J Neurol       Date:  2012-02-10       Impact factor: 4.849

5.  Inhibition by uric acid of free radicals that damage biological molecules.

Authors:  Sanae Muraoka; Toshiaki Miura
Journal:  Pharmacol Toxicol       Date:  2003-12

6.  Alcohol intake as a risk factor for fracture.

Authors:  John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse
Journal:  Osteoporos Int       Date:  2004-09-29       Impact factor: 4.507

7.  Uric acid as a CNS antioxidant.

Authors:  Gene L Bowman; Jackilen Shannon; Balz Frei; Jeffrey A Kaye; Joseph F Quinn
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study.

Authors:  Nancy E Lane; Neeta Parimi; Li-Yung Lui; Barton L Wise; Wei Yao; Yu-An Evan Lay; Peggy M Cawthon; Eric Orwoll
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

9.  Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women.

Authors:  K Lippuner; H Johansson; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-10-31       Impact factor: 4.507

10.  Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?

Authors:  Xu Duan; Feng Ling
Journal:  Med Hypotheses       Date:  2007-08-06       Impact factor: 1.538

View more
  29 in total

1.  Association of gout with osteoporotic fractures.

Authors:  Yanmao Wang; Runhua Zhou; Wanrun Zhong; Chengfang Hu; Shengdi Lu; Yimin Chai
Journal:  Int Orthop       Date:  2018-06-28       Impact factor: 3.075

2.  Serum uric acid is associated with quantitative ultrasound parameters in men: data from the Camargo cohort.

Authors:  J L Hernández; D Nan; J Martínez; E Pariente; I Sierra; J González-Macías; J M Olmos
Journal:  Osteoporos Int       Date:  2015-03-03       Impact factor: 4.507

3.  Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis.

Authors:  D Simon; J Haschka; C Muschitz; A Kocijan; A Baierl; A Kleyer; G Schett; S Kapiotis; H Resch; M Sticherling; J Rech; R Kocijan
Journal:  Osteoporos Int       Date:  2020-01-10       Impact factor: 4.507

4.  Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI.

Authors:  Mingxin Xu; Junlei Su; Jie Hao; Ni Zhong; Zhiyin Zhang; Ran Cui; Feng Li; Chunjun Sheng; Ge Zhang; Hui Sheng; Shen Qu
Journal:  J Bone Miner Metab       Date:  2017-11-09       Impact factor: 2.626

5.  Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population.

Authors:  Dan-Dan Yan; Jie Wang; Xu-Hong Hou; Yu-Qian Bao; Zhen-Lin Zhang; Cheng Hu; Wei-Ping Jia
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150

Review 6.  The association between serum uric acid level and the risk of fractures: a systematic review and meta-analysis.

Authors:  P Yin; H Lv; Y Li; Y Meng; L Zhang; P Tang
Journal:  Osteoporos Int       Date:  2017-05-09       Impact factor: 4.507

Review 7.  The role of uric acid in mineral bone disorders in chronic kidney disease.

Authors:  Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

8.  Relationship between serum uric Acid and bone mineral density in the general population and in rats with experimental hyperuricemia.

Authors:  Dihua Zhang; I Alexandru Bobulescu; Naim M Maalouf; Beverley Adams-Huet; John Poindexter; Sun Park; Fuxin Wei; Christopher Chen; Orson W Moe; Khashayar Sakhaee
Journal:  J Bone Miner Res       Date:  2015-06       Impact factor: 6.741

9.  Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.

Authors:  Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal
Journal:  Metabolism       Date:  2014-11-21       Impact factor: 8.694

10.  Higher serum uric acid is associated with higher lumbar spine bone mineral density in male health-screening examinees: a cross-sectional study.

Authors:  Jiwon Hwang; Jung Hye Hwang; Seungho Ryu; Joong Kyong Ahn
Journal:  J Bone Miner Metab       Date:  2018-01-25       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.